Hepatic

Mouse studies suggest inhibiting TGFBR1 could help treat cholangiopathic biliary liver diseases. In a mouse model of cholangiopathic disease, the TGFBR1 inhibitor galunisertib increased liver function and decreased cholangiocyte senescence in the liver compared with vehicle. Next steps include testing inhibitors of TGFBR1 and other TGFβ receptors in animal models of cholangiopathic biliary liver diseases.

Eli Lilly and Co. has galunisertib (LY2157299) in phase II testing for brain and liver cancers and phase I/II testing for pancreatic cancer...